In poultry and pig production, water-soluble oral powders based on SMD sodium are handled not as the low-solubility free base but as a milled sodium salt blended into a drinking-water medication with a target active content of 10.0–20.0% w/w SMD base equivalent. The formulation addition ratio is derived from the approved dose and measured daily water intake; a stock solution dosed through a medicator at 1.0–5.0% v/v is diluted to a final drinking-water concentration of 0.1–0.4 g/L, depending on species, age, disease condition, and national registration. The dry blend is prepared in a low-shear ribbon blender at 60–70% of rated capacity, using SMD sodium pre-milled to D90 ≤ 150 µm and lactose monohydrate as the primary carrier; anhydrous sodium citrate at 2.0–4.0% w/w holds reconstituted solution pH above 8.0 and prevents precipitation of the free acid in hard water. Blend uniformity is assessed by stratified thief sampling with near-infrared verification, and the acceptance limit is set at RSD ≤ 5.0% for active content. The powder is filled into foil-lined heat-sealed sachets at residual moisture below 2.0% w/w to limit hydrolysis of the sulfonamide bond. Microbiological quality of the non-sterile powder is assessed by Ph. Eur. 2.6.12 and 2.6.13, with total aerobic microbial count below 10³ CFU/g and absence of Escherichia coli in 1 g. Compliance for food-producing use is anchored to Regulation (EU) No 37/2010, which assigns a sulfonamide group marker residue limit of 100 µg/kg in muscle, fat, liver, and kidney for bovine, ovine, caprine, porcine, and poultry species, and the same limit in milk; residue depletion studies are validated under VICH GL18. Terminal product forms include 100 g, 500 g, and 1 kg water-soluble sachets, plus bulk drums for automatic proportioner lines. A field-scale limitation occurs when water supplies carry bicarbonate, calcium, and magnesium: exposure to atmospheric CO2 can depress pH and yield needle-like free-acid crystals that block header-tank filters; therefore the powder must not be mixed with acidic electrolyte solutions, tetracycline stock solutions, or chlorine dioxide disinfectant in the same line without potable-water flushing. The operating boundary is a reconstituted solution temperature of 8–25 °C and a use window of 24 h for non-preserved drinking-water systems.

What Limits Terminal Sterilization of Sulfamethoxydiazine Sodium Injection at High Concentration?

High-concentration injectable solutions are prepared from SMD sodium rather than the free base because the sodium salt provides sufficient aqueous solubility for sterile filtration and, where stability permits, terminal steam sterilization. The solution is formulated to a target active concentration of 100–200 mg SMD base/mL, equivalent to 10.0–20.0% w/v formulation strength. The addition ratio is controlled by pH adjustment with 1 M sodium hydroxide to a final solution pH of 9.5–10.5; the free acid precipitates below pH 8.0 as needle-like crystals that can pass through in-line filters and later block hypodermic needles. The solution is sparged with pharmaceutical-grade nitrogen, then sterile-filtered through a 0.22 µm PVDF membrane and filled under Grade A airflow into amber borosilicate vials with a nitrogen-flushed headspace oxygen content below 2.0% v/v. Terminal sterilization by steam at 121 °C for 15 min is applied only where thermal degradation data show assay loss below 2.0% and total impurities within the registered specification; otherwise, aseptic filling is used. Sterility testing follows Ph. Eur. 2.6.1, bacterial endotoxin testing follows Ph. Eur. 2.6.14, and sub-visible particulate contamination follows Ph. Eur. 2.9.19; filter integrity is verified by post-use bubble point and container closure integrity by dye ingress or vacuum decay. Depyrogenation of vials is performed in a dry-heat tunnel at 250 °C for 30 min. The compliance anchor for food-producing species is Regulation (EU) No 37/2010, with residue depletion studies validated under VICH GL18 to establish the withdrawal period. Terminal product types are 50 mL and 100 mL multidose vials for cattle, sheep, and pig administration by intramuscular or subcutaneous injection; a 250 mL presentation is used where registered for equine or camelid applications. A known operational boundary is that SMD sodium solutions are incompatible with strongly acidic vehicles and with containers that leach divalent cations; if the pH drifts below 8.0, precipitation compromises dose accuracy, filtration, and syringability. Published data for the exact thermal degradation rate in high-concentration SMD injection is limited; formulators therefore run hold-time studies on each vial configuration rather than relying on a universal sterilization cycle.

SMD Tablet and Bolus Compression and the Disintegration Lag in Ruminant Fluid

For SMD tablet compression, the primary processing constraint is a disintegration lag in rumen-reticulum fluid because the un-ionized sulfonamide is poorly soluble at pH 6.0–7.0. To offset this, the formulation is wet granulated rather than directly compressed: SMD base at a unit dose of 250 mg or 500 mg per tablet is combined with microcrystalline cellulose, 2.0–4.0% w/w sodium starch glycolate, and 2.0% w/w crospovidone, then granulated with a 5.0% w/w aqueous povidone K30 solution in a high-shear granulator. The API addition ratio in the tablet core is 50.0–70.0% w/w, with the balance composed of disintegrant, binder, and magnesium stearate. Granule flow is controlled to a Hausner ratio below 1.25 and Carr index below 20% before compression. The wet mass is dried in a fluid-bed dryer at an inlet air temperature of 55–65 °C until loss on drying is 1.5–2.5% w/w, then passed through a 0.8 mm oscillating sieve. Compression is performed on a rotary tablet press at 25–35 rpm with a target hardness of 80–120 N, a friability below 1.0% w/w, and a disintegration time below 15 min in 900 mL phosphate buffer pH 6.8 when tested according to Ph. Eur. 2.9.1. Dissolution testing follows Ph. Eur. 2.9.3 with apparatus II at 50 rpm, and uniformity of dosage units follows Ph. Eur. 2.9.40. For food-producing species, the residue compliance path remains Regulation (EU) No 37/2010, with the sulfonamide group MRL of 100 µg/kg in edible tissues; extra-label use is governed by national veterinary prescription rules. Terminal product types include film-coated tablets for calves, sheep, and goats, and elongated oral boluses for pre-ruminant calves. An operational boundary is required when relative humidity exceeds 60%: SMD base picks up moisture and can bind to punch faces during compression; drying of the granule before compression and dehumidification of the compression suite to 45–55% RH are mandatory. The formulation should not include amine-based film-coating additives that generate localized alkaline microenvironments sufficient to accelerate sulfonamide oxidation.

Compound feed manufacture requires SMD to be introduced not as pure micronized powder but as a prediluted granulated premix, because direct addition creates carryover risk and inhomogeneous distribution in finished feed. The premix is manufactured by first blending SMD base or sodium salt with calcium carbonate or corn cob carrier to an active content of 10.0–20.0% w/w, then dry granulating the blend in a roller compactor and sieving to a granule fraction of 0.5–1.0 mm. The premix is diluted into final feed through a two-step sequence in a ribbon mixer, typically at 0.10–0.20% w/w final feed inclusion to deliver a therapeutic intake of 100–200 mg/kg feed; the exact addition ratio is calculated from species-specific daily feed intake and must be recalculated when feed energy density changes because voluntary intake varies inversely with metabolizable energy. Mixer uniformity is verified by tracer salt recovery with acceptance at RSD ≤ 5.0%, and the cleanout protocol is validated by swab testing for sulfonamide residues after a rinse batch. The regulatory frame for medicated feed in the European Economic Area is Regulation (EU) 2019/4, which sets harmonized rules for manufacture, placing on the market, and use of medicated feed and feed intermediates, and requires carryover control and batch records that allow traceability to the API lot. For the API itself, EU GMP Part II for active substances used as starting materials and the FAMI-QS Code provide the compliance framework; residue limits in food-producing animals remain anchored to Regulation (EU) No 37/2010 at 100 µg/kg in muscle, fat, liver, kidney, and milk. Terminal product types are 5 kg and 20 kg barrier bags of SMD premix, and the resulting medicated feed is delivered as meal, pellets, or crumbles depending on the downstream feed line. A process limitation arises when the same mixer is used for ionophore coccidiostats or mineral premixes: electrostatic adhesion and dust extraction can transfer SMD into non-target batches, so dedicated bins or validated cleaning procedures are required at the 1% carryover threshold set for antimicrobial active substances under Regulation (EU) 2019/4.

When Sulfamethoxydiazine Is Filled into Hard Gelatin Capsules for Horses Not Intended for Human Consumption

When hard gelatin capsules are selected for a veterinary hospital, compounding pharmacy, or small-batch GMP line, SMD base is pre-sieved through a 180 µm aperture and triturated with microcrystalline cellulose and 2.0% w/w magnesium stearate before capsule filling. The unit dose is fixed at 200 mg or 500 mg SMD base per capsule, corresponding to an API addition ratio of 65.0–75.0% w/w in the powder fill, depending on capsule size and bulk density. Filling is performed on a dosator-type or tamping-pin capsule machine at 20–25 °C and 65–75% RH, because lower humidity increases electrostatic charging and higher humidity softens gelatin shells. In-process weight control is performed by electronic checkweighing at intervals no greater than 30 min, with acceptance limits of ±7.5% for individual capsule mass according to Ph. Eur. 2.9.5; content uniformity testing follows Ph. Eur. 2.9.40, and dissolution testing follows Ph. Eur. 2.9.3 in 900 mL of 0.1 M hydrochloric acid at 50 rpm. The compliance anchor for the API remains EU GMP Part II and the relevant veterinary pharmacopoeial monograph; stability testing follows VICH GL3, with accelerated conditions at 40 °C/75% RH for six months in the registration dossier. If the capsules are used in companion animals or horses not intended for food production, EU residue limits do not apply, but prescription documentation and batch release records must still conform to national veterinary pharmaceutical legislation. Terminal product types are 200 mg or 500 mg hard gelatin capsules packed in amber HDPE bottles with desiccant and induction-sealed caps, or in PVC/aluminum blister packs. An operational boundary is that SMD base is photosensitive; capsule fill rooms with daylight-spectrum fluorescent lighting should be filtered to remove UV below 400 nm, or the bulk powder should be held in amber-lined drums. Gelatin cross-linking caused by trace aldehydes in packaging or by exposure to high temperature above 40 °C will delay dissolution and must be excluded by stability testing.

Oral granules for small ruminants and weaned piglets demand a different particle architecture than feed premix because the product must adhere to feed pellets or be accepted from a drenching spoon. The granule formulation uses a fluid-bed top-spray granulation process in which SMD base is suspended in a binder solution of maltodextrin and sodium starch glycolate and sprayed onto a seed bed of sucrose or lactose at an inlet air temperature of 50–60 °C. The active content is set at 5.0–10.0% w/w SMD base equivalent, with a final granule size fraction between 0.8 mm and 1.4 mm to minimize dust and segregation. The addition ratio in the final feed top-dressing is calculated from body weight and feed intake; practical use rates are set by the approved therapeutic dose rather than a fixed independent value, but the active concentration in the granule remains fixed within the stated range. The granules are dried to a moisture content below 2.5% w/w and packaged in aluminum-laminate pouches of 100 g and 250 g to block water vapor and light. The compliance path includes the sulfonamide group MRL of 100 µg/kg in edible tissues under Regulation (EU) No 37/2010, with residue depletion and withdrawal periods established under VICH GL18; for mixing homogeneity, Ph. Eur. 2.9.40 and 2.9.5 are applied to the finished granule sachet. Terminal product types are top-dressing granules and oral suspension granules for reconstitution in water before drenching. An operational limitation appears when ambient humidity exceeds 60% RH: the hygroscopic granule surface becomes sticky and can bridge in the drying chamber or block the filling auger; therefore fluid-bed drying and packaging are conducted under dehumidified air at 35–45% RH. The granule should not be blended with alkaline earth mineral supplements that release divalent cations, because these ions can complex with sulfonamide residues and slow dissolution in the gastrointestinal tract.